---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023827"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:46:13.075114+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened

## Summary
- Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.
- Cash, equivalents, and investments $395.1M; expected to fund operations into 2025.
- NKX019 dose expansion cohorts opened; clinical update expected by year-end 2022.
- NKX101 data for r/r AML timeline pushed to first half of 2023.
- SITC presentations on NKX019+CD20 mAb combination and scalable NK cell manufacturing.

## SEC filing metadata
- accession: 0000950170-22-023827
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/nktx-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023827
- JSON: https://secwatch.observer/filing/0000950170-22-023827.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023827.txt

## Key facts
- Earnings Releases
  Nkarta, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 9, 2022, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.